低剂量重组改构人肿瘤坏死因子联合化疗治疗晚期非小细胞肺癌的临床疗效观察

Clinical effect of low-dose recombinant mutant human tumor necrosis factor combined with chemotherapy in the treatment of advanced non small cell lung cancer

目的观察低剂量重组改构人肿瘤坏死因子(rmh TNF)联合化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法选取重庆市中医院2014年5月—2015年6月收治的80例晚期NSCLC患者。随机分为试验组48例和对照组32例。试验组给予rmh TNF联合化疗方案治疗,对照组给予单纯化疗,两组均采用NP、TP方案化疗。比较两组患者的临床疗效及毒副作用发生情况。结果试验组有效率为33.3%,高于对照组的21.9%,差异有统计学意义(P<0.05)。治疗前两组患者KPS评分比较,差异无统计学意义(P>0.05);治疗后试验组KPS评分高于对照组,差异有统计学意义(P<0.05)。结论静脉滴注低剂量的rmh TNF联合化疗药物治疗NSCLC的近期疗效理想,可显著改善患者的生活质量。

Objective To observe the clinical efficacy of low- dose recombinant mutant human tumor necrosis factor( rmh TNF) combined with chemotherapy in the treatment of advanced non- small cell lung cancer( NSCLC). Methods A total of 80 advanced NSCLC patients from May 2014 to June 2015 in Traditional Chinese Medicine Hospital of Chongqing were selected,which were randomly divided into experiment group( 48 cases) and control group( 32 cases). The experiment group were treated with rmh TNF combined with chemotherapy,the control group were treated with chemotherapy. Both of groups were treated with NP and TP schemes. The clinical effect and adverse event rate between the two groups were compared. Results The clinical effective rate of experiment group( 33. 3%) was higher than control group( 21. 9%)( P < 0. 05). Before treatment,the KPS score between the two groups showed no significant differences( P > 0. 05); after treatment,the KPS score of experiment group was higher than control group( P < 0. 05). Conclusion The intravenous infusion of low- dose rmh TNF combined with chemotherapy has a better short- term effect in the treatment of NSCLC,the patient’s quality of life is greatly improved.